Open Access

Pre‑treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer

  • Authors:
    • Yuko Matsubara
    • Keiichiro Nakamura
    • Hirofumi Matsuoka
    • Chikako Ogawa
    • Hisashi Masuyama
  • View Affiliations

  • Published online on: August 19, 2019     https://doi.org/10.3892/mco.2019.1912
  • Pages: 376-382
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Low skeletal muscle mass (sarcopenia) is an important prognostic risk factor for the outcome of a variety of cancer types. The current study investigated whether skeletal muscle area (SMA), psoas area (PA) and psoas major volume (PV) are associated with progression‑free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (OC). A total of 92 OC patients were enrolled in the present study. Pre‑treatment with SMA and PA was assessed using computed tomography (CT) and PV was calculated using a three‑dimensional‑CT (3D‑CT). The clinical factors associated with sarcopenia and prognosis were retrospectively evaluated. For all patients, the median PFS and OS were 19 and 32 months, respectively. Patients exhibiting lower PV (<195.6 cm3) had significantly poorer PFS and OS compared with patients exhibiting higher PV (≥195.6 cm3; P=0.018 and P=0.006), while those with low SMA (<92.92 cm2) had significantly worse OS than patients with higher SMA (≥92.92 cm2; P=0.030). PV was also demonstrated to be superior to SMA and PA in prognosis prediction. PV by 3D‑CT can serve as an indicator of poor prognosis in patients with OC.

References

1 

American Cancer Society: Cancer Facts & Figures 2009. American Cancer Society; Atlanta, GA: 2009

2 

Ushijima K: Current status of gynecologic cancer in Japan. J Gynecol Oncol. 20:67–71. 2000. View Article : Google Scholar

3 

Fathalla MF: Factors in the causation and incidence of ovarian cancer. Obstet Gynecol Surv. 27:751–768. 1972. View Article : Google Scholar : PubMed/NCBI

4 

Vergote IB, Kaern J, Abeler VM, Pettersen EO, De Vos LN and Tropé CG: Analysis of prognostic factors in stage I epithelial ovarian carcinoma: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol. 169:40–52. 1993. View Article : Google Scholar : PubMed/NCBI

5 

Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB and Baracos VE: Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 31:1539–1547. 2013. View Article : Google Scholar : PubMed/NCBI

6 

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12:489–495. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ and Baracos VE: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 33:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI

8 

Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, Heymsfield SB and Heshka S: Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 97:2333–2338. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Moses AW, Slater C, Preston T, Barber MD and Fearon KC: Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer. 90:996–1002. 2004. View Article : Google Scholar : PubMed/NCBI

10 

Joglekar S, Nau PN and Mezhir JJ: The impact of sarcopenia on survival and complications in surgical oncology: A review of the current literature. J Surg Oncol. 112:503–509. 2015. View Article : Google Scholar : PubMed/NCBI

11 

Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L and Baracos VE: Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol. 9:629–635. 2008. View Article : Google Scholar : PubMed/NCBI

12 

Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S and Wang S: Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol. 18:3579–3585. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Harimoto N, Shirabe K, Yamashita YI, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, Maehara Y, Nishie A and Yamanaka T: Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg. 100:1523–1530. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Yankelevitz DF, Reeves AP, Kostis WJ, Zhao B and Henschke CI: Small pulmonary nodules: Volumetrically determined growth rates based on CT evaluation. Radiology. 217:251–256. 2000. View Article : Google Scholar : PubMed/NCBI

15 

Jennings SG, Winer-Muram HT, Tarver RD and Farber MO: Lung tumor growth: Assessment with CT-comparison of diameter and cross-sectional area with volume measurements. Radiology. 231:866–871. 2004. View Article : Google Scholar : PubMed/NCBI

16 

Malietzis G, Aziz O, Bagnall NM, Johns N, Fearon KC and Jenkins JT: The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: A systematic review. Eur J Surg Oncol. 41:186–196. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Sarkozy C, Camus V, Tilly H, Salles G and Jardin F: Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: Physiopathological significance and predictive value in the immunochemotherapy era. Leuk Lymphoma. 56:1959–1968. 2015. View Article : Google Scholar : PubMed/NCBI

18 

Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, Watadani T, Nakagomi R, Kondo M, Nakatsuka T, Minami T, et al: Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 63:131–140. 2015. View Article : Google Scholar : PubMed/NCBI

19 

McMillan DC, Watson WS, O'Gorman P, Preston T, Scott HR and McArdle CS: Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 39:210–213. 2001. View Article : Google Scholar : PubMed/NCBI

20 

Wang CS and Sun CF: C-reactive protein and malignancy: Clinico-pathological association and therapeutic implication. Chang Gung Med J. 32:471–482. 2009.PubMed/NCBI

21 

Funovics PT, Edelhauser G, Funovics MA, Laux C, Berzaczy D, Kubista B, Kotz RI and Dominkus M: Pre-operative serum C-reactive protein as independent prognostic factor for survival but not infection in patients with high-grade osteosarcoma. Int Orthop. 35:1529–1536. 2011. View Article : Google Scholar : PubMed/NCBI

22 

Omichi C, Nakamura K, Haraga J, Masuyama H and Hiramatsu Y: Glasgow prognostic score is an independent marker for poor prognosis with all cases of epithelial ovarian cancer. Cancer Med. 5:1074–1080. 2016. View Article : Google Scholar : PubMed/NCBI

23 

Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030. 2003. View Article : Google Scholar : PubMed/NCBI

24 

Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH, Horgan PG and McMillan DC: Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 97:1266–1270. 2007. View Article : Google Scholar : PubMed/NCBI

25 

McSorley ST, Black DH, Horgan PG and McMillan DC: The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer. Clin Nutr. 37:1279–1285. 2018. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 11 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Matsubara, Y., Nakamura, K., Matsuoka, H., Ogawa, C., & Masuyama, H. (2019). Pre‑treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer. Molecular and Clinical Oncology, 11, 376-382. https://doi.org/10.3892/mco.2019.1912
MLA
Matsubara, Y., Nakamura, K., Matsuoka, H., Ogawa, C., Masuyama, H."Pre‑treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer". Molecular and Clinical Oncology 11.4 (2019): 376-382.
Chicago
Matsubara, Y., Nakamura, K., Matsuoka, H., Ogawa, C., Masuyama, H."Pre‑treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer". Molecular and Clinical Oncology 11, no. 4 (2019): 376-382. https://doi.org/10.3892/mco.2019.1912